This page shows the latest Erivedge news and features for those working in and with pharma, biotech and healthcare.
The small-molecule drug blocks part of the Sonic hedgehog pathway, which is also targeted by other cancer drugs including Roche’s Erivedge (vismodegib) and Novartis’ Odomzo (sonidegib) for basal cell ... Erivedge has been discontinued for AML and
Roche’s Erivedge (vismodegib) - which was made available via the old CDF in 2013 - is also set to be cut from the scheme, but patients who are currently receiving the drug
There are already two SMO (smoothened) inhibitors on the market - Novartis' Odomzo (sonidegib) and Roche's Erivedge (vismodegib) - and both are approved to treat a form of skin cancer known as ... Sales of Erivedge were around $150m in the first nine
It will compete in the marketplace against Roche's Erivedge (vismodegib), another SMO inhibitor that has been on the market since 2012 and achieved sales of 72m Swiss francs ($75m) in ... Neither drug is expected to be a big seller thanks to the small
The pill will compete against Roche's Erivedge (vismodegib), which was the first oral drug for BCC to see approval in 2012, although neither medicine is expected to be a blockbuster
This pathway is also targeted by Roche's Erivedge (vismodegib), which was granted approval as a BCC therapy in the US in 2012 and in Europe last year. ... Erivedge sales rocketed more than 160 per cent to reach 75m Swiss francs ($84m) last year has been
More from news
Approximately 3 fully matching, plus 7 partially matching documents found.
The small-molecule drug blocks part of the Sonic hedgehog pathway, which is also targeted by other cancer drugs including Roche’s Erivedge (vismodegib) and Novartis’ Odomzo (sonidegib) for basal cell
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
During this time he worked on major cancer medicines, such as melanoma drug Zelboraf (vemurafenib) and Erivedge (vismodegib) for patients with unresectable, locally advanced or metastatic basal cell carcinoma.
Curis also worked with Roche to Erivedge (vismodegib), which recently won approval for the treatment of advanced basal cell carcinoma (BCC).
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
For those who can imagine better, Page & Page and Partners (P&P) is home to meaningful encounters of a marketing, communication...